CDA | Evidence Driven
CDA | Evidence Driven

Evusheld for the Treatment of Mild to Moderate COVID-19

Details

Files
Project Status:
Completed
Project Line:
Health Technology Review
Project Sub Line:
Technology Review
Project Number:
HC0041-000
Expected finish date:

Tixagevimab and cilgavimab (Evusheld) is a combination of long-acting monoclonal antibodies for intramuscular administration for the treatment of mild to moderate COVID-19. Canada's Drug Agency conducted a review of the evidence and convened an Implementation Advice Panel to prioritize the patient populations that are most likely to benefit from treatment with Evusheld.

 

Files

Evusheld for the Treatment of Mild to Moderate COVID-19 View PDF
Last Updated : October 26, 2022